Abbott Laboratories said on Tuesday the U.S. FDA has approved its heart valve repair device designed for patients at risk of complications or death during open-heart surgeries.
The device, TriClip, already approved in over 50 countries, aims to treat tricuspid regurgitation (TR), a potentially fatal condition where the valve separating the right lower chamber of the heart from the right upper does not close properly.
